Champions Biotechnology signs licensing agreement with Yale University and Southern Research

Posted on: Thu, 19 Nov 2009 13:40:00 EST


Symbols: CSBRE
Nov 19, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
CSBRE | Quote | Chart | News | PowerRating -- Champions Biotechnology, Inc. (CBI), an oncology drug development company, has signed an exclusive licensing agreement with Yale University and Southern Research Institute for the development of Bithionol for cancer treatment. All the entities are based in the US.

Under the terms of the agreement, CBI will have exclusive rights and be responsible for the further development of Bithionol for all oncology indications. Yale and Southern Research will receive an upfront payment and will be eligible to receive milestone payments and royalties. Additionally, the parties have agreed upon certain terms favorable to developing world markets.

CBI will use its predictive Biomerk TumorgraftT(TM) platform to assess the efficacy of the compound-alone and in combination with other compounds-to determine its optimal application and enable efficient clinical development. Upon successful results, CBI will move the compound forward into human clinical trials.

Deal Type    Partnership
Sub-Category Development,Acquisition of Rights
Deal Status Announced: 2009-11-18

Deal Participants

Partner 1 (Company) Southern Research Institute
Partner 2 (Company) Champions Biotechnology, Inc.
Partner 3 (Company) Yale University

For full details on (CSBRE) CSBRE. (CSBRE) has Short Term PowerRatings at TradingMarkets. Details on (CSBRE) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.